How To Manage Type 1 And Type 2 Diabetes?

How To Manage Type 1 And Type 2 Diabetes
Type 1 and type 2 differences – Below is a guide to some of the main differences between type 1 and type 2.

Type 1 Type 2
What is happening? Your body attacks the cells in your pancreas which means it cannot make any insulin. Your body is unable to make enough insulin or the insulin you do make doesn’t work properly.
Risk factors We don’t currently know what causes type 1 diabetes. We know some things can put you at risk of having type 2 like weight and ethnicity.
Symptoms The symptoms for type 1 appear more quickly. Type 2 symptoms can be easier to miss because they appear more slowly.
Management Type 1 is managed by taking insulin to control your blood sugar. You can manage type 2 diabetes in more ways than type 1. These include through medication, exercise and diet. People with type 2 can also be prescribed insulin.
Cure and Prevention Currently there is no cure for type 1 but research continues. Type 2 cannot be cured but there is evidence to say in many cases it can be prevented and put into remission.

Can you have diabetes 1 and 2 at the same time?

While people are not diagnosed with both type 1 and type 2 diabetes at the same time, those with type 1 may be at risk for also developing characteristics of type 2 diabetes over time. Type 1 diabetes is an autoimmune condition in which the body no longer produces insulin.

Can you get rid of type 1 or type 2 diabetes?

Here’s how healthier habits may help some people reverse or better manage the disease. – Diabetes is a very common but serious medical condition. According to the Centers for Disease Control and Prevention (CDC), more than 34 million Americans have it, with about 90-95% of them having type 2 diabetes. About 88 million people have prediabetes, a precursor to type 2 diabetes.

There is no cure for type 2 diabetes. But it may be possible to reverse the condition to a point where you do not need medication to manage it and your body does not suffer ill effects from having blood sugar levels that are too high. Making positive lifestyle changes such as eating a well-balanced diet, exercising regularly and getting down to a healthy weight (and maintaining it) are the key to possibly reversing or managing type 2 diabetes.

Other lifestyle changes may also help, including not smoking, getting enough sleep, limiting alcohol and managing stress. However, for some people this is still not enough and medication is needed to manage the condition.

Is metformin good for type 1 diabetes?

References –

  1. Chiang JL, Kirkman MS, Laffel LMB, Peters AL, Type 1 Diabetes Sourcebook Authors. Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care.2014;37:2034–54. Article PubMed Google Scholar
  2. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes control and complications trial. JAMA.1998;280:140–6. Article CAS PubMed PubMed Central Google Scholar
  3. Orchard TJ, Olson JC, Erbey JR, Williams K, Forrest KY-Z, Smithline Kinder L, Ellis D, Becker DJ. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care.2003;26:1374–9. Article PubMed Google Scholar
  4. Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, Parving I, Pietraszek L, Frandsen M, Rossing P, et al. Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study. PLoS One.2008;3:e3363. Article PubMed PubMed Central Google Scholar
  5. Pop A, Clenciu D, Anghel M, Radu S, Socea B, Mota E, Mota M, Panduru NM, RomDianeStudy Group. Insulin resistance is associated with all chronic complications in type 1 diabetes. J Diabetes.2016;8(2):220–8.
  6. Krochik AG, Botto M, Bravo M, Hepner M, Frontroth JP, Miranda M, Mazza C. Association between insulin resistance and risk of complications in children and adolescents with type 1 diabetes. Diabetes Metab Syndr.2015;9:14–8. Article PubMed Google Scholar
  7. Thorn LM, Forsblom C, Fagerudd J, Thomas MC, Pettersson-Fernholm K, Saraheimo M, Wadén J, Rönnback M, Rosengård-Bärlund M, Björkesten C-GA, et al. Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care.2005;28:2019–24. Article PubMed Google Scholar
  8. Metascreen Writing Committee, Bonadonna RC, Cucinotta D, Fedele D, Riccardi G, Tiengo A. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diabetes Care.2006;29:2701–7. Article Google Scholar
  9. Kilpatrick ES, Rigby AS, Atkin SL. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the diabetes control and complications trial. Diabetes Care.2007;30:707–12. Article CAS PubMed Google Scholar
  10. Lauria A, Barker A, Schloot N, Hosszufalusi N, Ludvigsson J, Mathieu C, Mauricio D, Nordwall M, Van der Schueren B, Mandrup-Poulsen T, et al. BMI is an important driver of β-cell loss in type 1 diabetes upon diagnosis in 10 to 18-year-old children. Eur J Endocrinol Eur Fed Endocr Soc.2015;172:107–13. Article CAS Google Scholar
  11. Yardley JE, Kenny GP, Perkins BA, Riddell MC, Goldfield GS, Donovan L, Hadjiyannakis S, Wells GA, Phillips P, Sigal RJ, et al. Resistance Exercise in Already-Active Diabetic Individuals (READI): study rationale, design and methods for a randomized controlled trial of resistance and aerobic exercise in type 1 diabetes. Contemp Clin Trials.2015;41:129–38. Article PubMed Google Scholar
  12. Sorensen JS, Birkebaek NH, Bjerre M, Pociot F, Kristensen K, Hoejberg AS, Frystyk J, Danish Society for Diabetes in Childhood and Adolescence. Residual β-cell function and the insulin-like growth factor system in Danish children and adolescents with type 1 diabetes. J Clin Endocrinol Metab.2015;100:1053–61. Article CAS PubMed Google Scholar
  13. Dejgaard TF, Knop FK, Tarnow L, Frandsen CS, Hansen TS, Almdal T, Holst JJ, Madsbad S, Andersen HU. Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes-a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study. BMJ Open.2015;5:e007791. Article PubMed PubMed Central Google Scholar
  14. Inzucchi SE, Maggs DG, Spollett GR, Page SL, Rife FS, Walton V, Shulman GI. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med.1998;338:867–72. Article CAS PubMed Google Scholar
  15. George P, McCrimmon RJ. Potential role of non-insulin adjunct therapy in Type 1 diabetes. Diabet Med J Br Diabet Assoc.2013;30:179–88. Article CAS Google Scholar
  16. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet.1998;352:854–65.
  17. Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care.2003;26:138–43. Article CAS PubMed Google Scholar
  18. Särnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol Eur Fed Endocr Soc.2003;149:323–9. Article Google Scholar
  19. Khan ASA, McLoughney CR, Ahmed AB. The effect of metformin on blood glucose control in overweight patients with type 1 diabetes. Diabet Med J Br Diabet Assoc.2006;23:1079–84. Article CAS Google Scholar
  20. Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N, Drouin P, Guerci B. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care.2002;25:2153–8. Article CAS PubMed Google Scholar
  21. Jacobsen IB, Henriksen JE, Beck-Nielsen H. The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol.2009;105:145–9. Article CAS PubMed Google Scholar
  22. Konrad K, Datz N, Engelsberger I, Grulich-Henn J, Hoertenhuber T, Knauth B, Meissner T, Wiegand S, Woelfle J, Holl RW, et al. Current use of metformin in addition to insulin in pediatric patients with type 1 diabetes mellitus: an analysis based on a large diabetes registry in Germany and Austria. Pediatr Diabetes.2015;16:529–37.
  23. DeGeeter M, Williamson B. Alternative agents in type 1 diabetes in addition to insulin therapy: Metformin, alpha-Glucosidase inhibitors, Pioglitazone, GLP-1 agonists, DPP-IV inhibitors, and SGLT-2 inhibitors.J. Pharm Pract.2016;29(2):144–59.
  24. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation.2002;106:3143–421. Google Scholar
  25. Urakami T, Morimoto S, Owada M, Harada K. Usefulness of the addition of metformin to insulin in pediatric patients with type 1 diabetes mellitus. Pediatr Int Off J Jpn Pediatr Soc.2005;47:430–3.
  26. Moon RJ, Bascombe, L-A, Holt RIG. The addition of metformin in type 1 diabetes improves insulin sensitivity, diabetic control, body composition and patient well-being. Diabetes Obes Metab.2007;9:143–5.
  27. Burchardt P, Zawada A, Tabaczewski P, Naskręt D, Kaczmarek J, Marcinkaniec J, Wierusz-Wysocka B, Wysocki H. Metformin added to intensive insulin therapy reduces plasma levels of glycated but not oxidized low‑density lipoprotein in young patients with type 1 diabetes and obesity in comparison with insulin alone: a pilot study. Pol Arch Med. Wewnętrznej.2013;123:526–32.
  28. Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, Parving I, Pietraszek L, Frandsen M, Rossing P, et al. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab.2009;11:966–77.
  29. Schwab KO, Doerfer J, Hecker W, Grulich-Henn J, Wiemann D, Kordonouri O, Beyer P, Holl RW, DPV Initiative of the German Working Group for Pediatric Diabetology. Spectrum and prevalence of atherogenic risk factors in 27,358 children, adolescents, and young adults with type 1 diabetes: cross-sectional data from the German diabetes documentation and quality management system (DPV). Diabetes Care.2006;29:218–25.

Download references

What is a 1.5 diabetes?

I’ve been diagnosed with LADA — latent autoimmune diabetes in adults. What’s the difference between it and other forms of diabetes? – Answer From M. Regina Castro, M.D. Latent autoimmune diabetes in adults (LADA) is a slow-progressing form of autoimmune diabetes.

  • Like the autoimmune disease type 1 diabetes, LADA occurs because your pancreas stops producing adequate insulin, most likely from some “insult” that slowly damages the insulin-producing cells in the pancreas.
  • But unlike type 1 diabetes, with LADA, you often won’t need insulin for several months up to years after you’ve been diagnosed.

Many researchers believe LADA, sometimes called type 1.5 diabetes, is a subtype of type 1 diabetes, while others do not recognize it as a distinct entity. Other researchers believe diabetes occurs on a continuum, with LADA falling between type 1 and type 2 diabetes.

  • People who have LADA are usually over age 30.
  • Because they’re older when symptoms develop than is typical for someone with type 1 diabetes and because initially their pancreases still produce some insulin, people with LADA are often misdiagnosed with type 2 diabetes.
  • If you’ve been diagnosed with type 2 diabetes and you’re lean and physically active or you’ve recently lost weight without effort, talk with your doctor about whether your current treatment is still the best one for you.

At first, LADA can be managed by controlling your blood sugar with diet, losing weight if appropriate, exercise and, possibly, oral medications. But as your body gradually loses its ability to produce insulin, you’ll eventually need insulin shots. More research is needed before the best way to treat LADA is established.

Do both type 1 and type 2 diabetes need insulin?

Posted on December 7, 2017 by 3340 How well do you know the difference between Type 1 and Type 2 diabetes? While the conditions may be similar, the causes and treatments for each are very different. Type 1 diabetes is an autoimmune disease often diagnosed in children, teens and young adults, although it can be diagnosed at any age.

  1. Type 2 diabetes, however, is more commonly diagnosed in those who are 45 years of age and older.
  2. In recent years, Type 2 diagnoses among younger people have become more common than in the past.
  3. Type 2 diabetes is a condition in which your body is still making insulin, but your body is insulin resistant.

Insulin is necessary for blood sugars to enter cells, so being insulin resistant means your body doesn’t handle blood sugars very well,” said Arti Bhan, M.D., an endocrinologist who specializes in diabetes care. “On the other hand, Type 1 diabetes is a condition in which your pancreas either does not make insulin at all, or doesn’t make enough insulin.

This lack of insulin causes your blood sugars to elevate.” To test your knowledge of Type 1 and Type 2 diabetes, see if you can answer these true and false questions correctly. True or False? Insulin injections are only used to treat Type 1 Diabetes. FALSE, “Someone with Type 1 diabetes will always require insulin injections, because their body produces little or no insulin, but someone with Type 2 diabetes may require insulin injections as part of their treatment plan as well,” said Eileen Labadie, Henry Ford Health diabetes education specialist.

“Type 2 diabetes is more commonly treated with healthy lifestyle modifications and medication, such as Metformin.” True or False? Type 1 Diabetes is far less common than Type 2 diabetes. TRUE, The estimates show that more than 29 million people have some form of diabetes, but Type 1 affects only around five percent of all people with diabetes in the United States.

In addition to the number of people diagnosed with Type 2 diabetes, there may be many more people with the condition who don’t know they have it, The symptoms are often subtle and develop over several years, so the condition can go unnoticed for a long time. “To avoid developing Type 2 diabetes, people should avoid processed foods and aim for 150 minutes of moderate exercise per week,” Dr.

Bhan added. She also recommends that those at risk for developing the disease should also know their “diabetes ABCs” – A stands for A1C level (results of a blood sugar or glucose test), B stands for blood pressure and C stands for cholesterol. You should also be mindful of the three S’s, which include smoking cessation, stress reduction and sleeping an adequate amount,

  1. True or False? Someone with Type 1 Diabetes can consume as many sugar-free treats as they want, because sugar is what Type 1 diabetic patients need to avoid. FALSE,
  2. Sugar free does not always mean carbohydrate free,” said Labadie.
  3. Sugar-free pies, candy and cakes may have other ingredients that contain a lot of calories and carbohydrates.

While sugar is a form of carbohydrate, the first thing a patient with Type 1 diabetes should look at on a food label is total carbohydrates.” Diabetes is a serious disease that can lead to debilitating and even fatal consequences. But the good news is that both Type 1 and Type 2 diabetes can be managed with an effective treatment plan, so talk to your doctor about the best plan to care for your condition and what resources are available to keep you healthy.

  • To learn more about diabetes prevention and management, or to book an appointment with a Henry Ford diabetes specialist, please visit, Dr.
  • Arti Bhan is the division head of endocrinology for Henry Ford Health and sees patients for diabetes, thyroid disorders and other conditions at Henry Ford Medical Centers in Detroit and Novi.

Henry Ford Health is a partner in the American Medical Group Foundation’s Together 2 Goal® campaign, a national effort to improve care for 1 million people with Type 2 diabetes.